In The News: School of Integrated Health Sciences

MSN

H-bombs use a combination of nuclear fission and fusion and are far more powerful than atomic bombs.

Yahoo!

Seven years after the end of WWII, the US detonated the world's first hydrogen bomb.

Insider

The world's first nuclear weapon — the atom bomb — devastated the Japanese cities of Hiroshima and Nagasaki in 1945.

Medscape

Clinicians from Switzerland are urging caution when prescribing an anti-amyloid medication in a patient with Alzheimer's disease (AD) also taking a selective serotonin reuptake inhibitor (SSRI) antidepressant.

La Provincia

Who doesn't like to find a bowl full of juicy strawberries when they open the fridge? Strawberries are one of the most appreciated fruits in gastronomy due to their exquisite flavor, but we rarely consider their healthy qualities when enjoying them. However, these fruits have an extensive list of benefits, some of which have been scientifically supported in recent studies.

El Mundo Instante

Strawberries, blueberries and blackberries share beneficial properties for memory

Drug Discovery World

A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies.

La Razón

It could also help prevent diseases such as Alzheimer's or diabetes.

Alzforum

With three positive and three negative Phase 3 trials of second-generation anti-amyloid antibodies to draw upon, Alzheimerologists now have more data to mine for what works and what does not. At last month’s Alzheimer’s Association International Conference in Amsterdam, scientists pored over gantenerumab and lecanemab data, hunting for clues of which parameters might predict success. And clues they found.

First for Women

Simply squeezing a lime into your water could be your ticket to dodging kidney stone pain

Alzheimer's News Today

93% of patients in study had an antibody response against beta-amyloid

MedPage Today

Patients starting SSRIs and lecanemab may warrant close monitoring